Project Grant R21AR086404
Award Date 9/10/25
Completion Date 8/31/27
Dollars Obligated $378K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,017,972 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Washington University in Missouri. The grant, with a performance period from September 10, 2025 to August 31, 2028, will fund research on the safety and efficacy of intra-articular corticosteroid injections for treating symptomatic osteoarthritis. Key objectives include investigating the...
- This federal Project Grant award of $1,950,412.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), to Wake Forest University Health Sciences. The funding supports research to define how the IRE1A-XBP1-NUPR1 signaling axis in immune cells and chondrocytes contributes to synovial inflammation, cartilage damage, and osteoarthritis pain. The...
- This federal Project Grant award of $646,506 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting the development of dual-action nanoparticle-loaded microparticles for the treatment of osteoarthritis (OA). The research aims to create innovative nanoparticle-based therapeutics that can stimulate the anabolic activity of chondroprogenitors to enhance cartilage...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded a $104,732 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the Oklahoma Medical Research Foundation (OMRF) for the project "Articular Microbiome for Prediction and Potential Therapy of Periprosthetic Joint Infections". The objective is to better understand how the native joint microbiome and phageome may contribute to the risk of...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting the development of an intraarticular (injectable) Wnt inhibitor therapy for the treatment of osteoarthritis (OA). OA is a common and debilitating joint disease affecting nearly 21 million people in the U.S. The $314,363 award, made on September 16, 2025, will fund the...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining the role of the NOTCH2 gene in articular inflammation and the development of osteoarthritis. The $404,187 grant, awarded on May 14, 2025, will enable researchers at the University of Connecticut Health Center to utilize a conditional NOTCH2 mouse model to: 1) determine...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $312,323 Project Grant to Knoubis Bio Inc. under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports the development of a novel bispecific biologic therapy for rheumatoid arthritis (RA) that targets the transmembrane tyrosine phosphatase PTPRS. The key activities under this Phase I project include conducting pharmacokinetic studies in mice...
- This Project Grant award, valued at $196,460.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The purpose of the award is to test a miniature knee joint system as a new tool to study the role of neuro-immune interactions in osteoarthritis pain. The University of Pittsburgh, the awardee, will use this novel microphysiological system with cartilage,...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,136,924 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the Rector & Visitors of the University of Virginia. The grant, awarded on July 1, 2025, is intended to support research on "Targeting Stage Specific Influxed Monocytes to Treat Acute and Chronic Back Pain". The project aims to use transgenic mouse models and a CCR2 antagonist to...
- The University of Southern California (USC) received a $628,174 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of this multi-year grant, with an ultimate completion date of March 31, 2030, is to support research into the cellular origins and molecular mechanisms underlying the development of arthrofibrosis, a debilitating...